Search

Displaying results 1471 - 1480 of 4591 in total
  1. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. … Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.

  2. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat par...

  3. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. Eculizumab was granted FD...

  4. Drug

    Trimetazidine

    go.drugbank.com/drugs/DB09069
    ApprovedInvestigational

    [A233215] It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate … [A233255,A233260] Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems.

  5. Drug

    Gallamine triethiodide

    go.drugbank.com/drugs/DB00483
    ApprovedWithdrawn

    It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198) … The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac

  6. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54106] Zemcelpro also contains [dorocubicel], a preparation CD34+ HSCs derived from the same cord blood sample and expanded _ex vivo_ using [UM-171].

  7. Drug

    Lenograstim

    go.drugbank.com/drugs/DB13144
    ApprovedWithdrawn

    Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

  8. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … positive results from the QuANTUM-First trial for FLT3-ITD positive AML, where quizartinib combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation, followed by

  9. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022...

  10. Drug

    Isosorbide

    go.drugbank.com/drugs/DB09401
    ApprovedInvestigational

    It was approved by the FDA in 1980, but has since been discontinued.